Request Appointment
622 West 168th StreetNew York, NY 10032
Overview of Dr. Mor
Dr. Adam Mor is a rheumatologist in New York, NY and is affiliated with multiple hospitals in the area, including NewYork-Presbyterian/Columbia University Irving Medical Center and NewYork-Presbyterian/Allen Hospital. He received his medical degree from Tel Aviv University Sackler and has been in practice 27 years. He is one of 11 doctors at NewYork-Presbyterian/Allen Hospital and one of 60 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Rheumatology. He has more than 100 publications and over 500 citings.
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2009 - 2011- NYU Grossman School of MedicineFellowship, Rheumatology, 2003 - 2005
Tel Aviv University SacklerClass of 1999
Certifications & Licensure
NY State Medical License 2011 - 2028
NJ State Medical License 2013 - 2017
Publications & Presentations
PubMed
- Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Joint Localization Matters.Yevgeniya Gartshteyn, Matthieu Paiola, Daniel M Portnoy, Robert Winchester, Adam Mor
The Journal of Rheumatology. 2026-07-15 - Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders.Justin Zhong, Ruijiang Song, Nacim Kerrouche, Xinyu Yu, Yotam Levin
Biodrugs. 2026-07-01 - Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors.Daniel M Portnoy, Matthieu Paiola, Carly Tymm, Robert Winchester, Adam Mor
Journal of Clinical Medicine. 2026-01-14
Journal Articles
- Review Targeting the Programmed Cell Death-1 Pathway in Rheumatoid ArthritisAdam Mor, Greg J. Silverman, Sabina Sandigursky, ScienceDirect
Press Mentions
“Double Life” of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune DiseasesMarch 10th, 2024- “Double Life” of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune DiseasesMarch 15th, 2024
Grant Support
- The role of tissue-resident T cells in osteoarthritis during the transition to inflammatory arthritis induced by immune checkpoint inhibitorsCOLUMBIA UNIVERSITY HEALTH SCIENCES2026–2028
- A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- Novel mechanisms regulating PD-1 signaling and functionCOLUMBIA UNIVERSITY HEALTH SCIENCES2016–2027
- PAG is a novel target in immunotherapyCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
